Obicetrapib: The Drug Targeting Both Heart Disease and Alzheimer's at Once

A drug in late-stage clinical trials has shown simultaneous cardiovascular risk reduction and meaningful improvements in Alzheimer’s disease biomarkers — a combination no previous therapy in either category has achieved. Peter Attia’s deep-dive on obicetrapib is worth understanding even if the drug is years from your medicine cabinet.

Context

Cardiovascular disease and Alzheimer’s share more mechanistic overlap than is commonly understood. Both are driven in part by lipid metabolism, chronic inflammation, and vascular health — which is why APOE4, the strongest genetic risk factor for late-onset Alzheimer’s, is also expressed in lipid transport. Despite this overlap, drug development has treated them as entirely separate problems. Statins address cardiovascular risk; nothing has reliably addressed Alzheimer’s risk in a preventive framework.

Obicetrapib, developed by NewAmsterdam Pharma, is a cholesteryl ester transfer protein (CETP) inhibitor — a drug class with a complicated history. Earlier CETP inhibitors failed in large trials despite their lipid effects. Obicetrapib appears to have succeeded where predecessors failed, delivering both lipid improvements and, unexpectedly, Alzheimer’s biomarker data that has put it on the longevity medicine radar.

The Detail

The mechanism is direct: CETP normally transfers cholesteryl esters from HDL to apolipoprotein B-containing lipoproteins. Inhibiting CETP raises HDL cholesterol and reduces LDL — obicetrapib achieves a 125% increase in HDL and a 33-50% reduction in LDL depending on whether it’s used as monotherapy or in combination. That’s a meaningful lipid effect in its own right.

The Alzheimer’s data comes from the BROADWAY trial — a Phase III study of 1,727 patients with cardiovascular disease that measured plasma p-tau217, a phosphorylated tau protein that is one of the most reliable early biomarkers of Alzheimer’s pathology. The results: obicetrapib significantly reduced absolute p-tau217 levels (p=0.0019 in the full analysis set; p=0.0215 in ApoE4 carriers). Over 12 months, the obicetrapib group showed a 1.1% increase in p-tau217 versus a 4.8% increase in the placebo group (p=0.01). In ApoE4/E4 homozygous carriers — the highest-risk genetic group — the drug produced a 20.5% reduction in p-tau217 levels over 12 months (p=0.010).

These are biomarker improvements, not cognitive outcomes. The data does not demonstrate that obicetrapib prevents Alzheimer’s disease — it demonstrates an effect on markers associated with Alzheimer’s pathology in a population being treated for cardiovascular risk. The PREVAIL trial, with over 9,500 randomized patients, is the cardiovascular outcomes study that will determine whether the lipid effects translate to actual MACE (major adverse cardiovascular events) reduction. EMA approval for obicetrapib is expected in the second half of 2026.

Anyone considering this or any therapeutic intervention should consult a qualified healthcare provider — this data is from an ongoing regulatory review process, not an approved treatment.

Content created with AI assistance and reviewed for accuracy.